Southeast Asset Advisors Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 1.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,146 shares of the biopharmaceutical company’s stock after purchasing an additional 691 shares during the period. Southeast Asset Advisors Inc.’s holdings in Pfizer were worth $1,609,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Fisher Asset Management LLC grew its holdings in Pfizer by 3.7% during the 2nd quarter. Fisher Asset Management LLC now owns 44,133,251 shares of the biopharmaceutical company’s stock worth $1,911,852,000 after acquiring an additional 1,559,405 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 2.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 35,948,881 shares of the biopharmaceutical company’s stock worth $1,557,306,000 after acquiring an additional 868,839 shares during the period. California Public Employees Retirement System boosted its position in shares of Pfizer by 14.0% during the 4th quarter. California Public Employees Retirement System now owns 20,333,138 shares of the biopharmaceutical company’s stock worth $887,541,000 after purchasing an additional 2,504,336 shares in the last quarter. Sanders Capital LLC boosted its position in shares of Pfizer by 3.3% during the 2nd quarter. Sanders Capital LLC now owns 18,749,080 shares of the biopharmaceutical company’s stock worth $910,953,000 after purchasing an additional 606,700 shares in the last quarter. Finally, APG Asset Management N.V. boosted its position in shares of Pfizer by 1.4% during the 4th quarter. APG Asset Management N.V. now owns 16,360,380 shares of the biopharmaceutical company’s stock worth $624,704,000 after purchasing an additional 228,300 shares in the last quarter. Institutional investors and hedge funds own 71.68% of the company’s stock.
In other Pfizer news, insider Alexander R. Mackenzie sold 30,000 shares of Pfizer stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the transaction, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Scott Gottlieb bought 3,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the transaction, the director now owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.
NYSE PFE traded down $0.08 during trading hours on Monday, hitting $36.83. The company’s stock had a trading volume of 18,729,176 shares, compared to its average volume of 20,086,764. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47. The company has a market capitalization of $206.20 billion, a PE ratio of 12.28, a price-to-earnings-growth ratio of 2.97 and a beta of 0.65. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The company’s 50-day simple moving average is $36.70 and its two-hundred day simple moving average is $40.78.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business had revenue of $13.26 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the firm earned $0.77 EPS. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.81 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd were given a $0.36 dividend. The ex-dividend date of this dividend was Thursday, August 1st. This represents a $1.44 annualized dividend and a yield of 3.91%. Pfizer’s payout ratio is 48.00%.
A number of equities analysts have recently issued reports on PFE shares. ValuEngine cut shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Saturday. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, July 29th. Morgan Stanley cut their price objective on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 27th. Bank of America cut shares of Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. Finally, DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective on the stock in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and four have issued a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $45.88.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: 52-Week High/Low
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.